11.01.2022 SHOP APOTHEKE EUROPE N.V.  NL0012044747

DGAP-News: SHOP APOTHEKE EUROPE: STRONG ACCELERATION OF SALES AND CUSTOMER GROWTH IN Q4.


 

DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): Development of Sales/Preliminary Results
SHOP APOTHEKE EUROPE: STRONG ACCELERATION OF SALES AND CUSTOMER GROWTH IN Q4.

11.01.2022 / 07:00
The issuer is solely responsible for the content of this announcement.


SHOP APOTHEKE EUROPE: STRONG ACCELERATION OF SALES AND CUSTOMER GROWTH IN Q4.

  • Q4 group revenues rose 21.0% vs. Q3.
  • Year-over-year sales growth for full-year 2021 is up 9.5% to EUR 1.06 billion.
  • Everything-but-Rx again strong: full-year sales up 22.4% vs. last year; in Q4 24.8%.
  • Number of active customers increased year-over-year by 1.6 million (0.5 million in Q4) to 7.9 million.
  • Milestone achieved towards customer-centric e-pharmacy platform through marketplace launch past December.


Sevenum, 11 January 2022. According to preliminary and unaudited calculations, SHOP APOTHEKE EUROPE's sales rose by 9.5% to EUR 1.06 billion. In the fourth quarter, sales amounted to EUR 287.8 million, an increase of 8.7% compared to previous year's strong fourth quarter. The group gained 1.6 million active customers during the year, thereof 0.5 million in the fourth quarter. The total number of active customers reached 7.9 million by the end of 2021.

Stefan Feltens, CEO of SHOP APOTHEKE EUROPE: "We are looking back on a very strong fourth quarter. We successfully returned to our previous growth path. In 2021, we made significant progress in implementing SHOP APOTHEKE EUROPE's strategy to become a customer-centric e-pharmacy platform: This includes the expansion of our digital health services, the roll-out of our same-day delivery service SHOP APOTHEKE NOW! to Germany's metropolitan areas and the opening of our new next-generation logistics centre. Most recently, in December, we took a major leap in broadening our product range by adding 20,000 health-care related products through the launch of our own marketplace in Germany. Last but not least, we have been ready for e-Rx in Germany since last summer. We successfully processed the first e-Rx prescriptions from customers since then."

In the full year 2021, the largest segment by sales, DACH, which includes SHOP APOTHEKE EUROPE's business activities in Germany, Austria and Switzerland, grew by 3.9% compared to 2020. Sales increased to EUR 847 million compared to EUR 815.4 million in the previous year; Rx sales were down 34.7% to EUR 143.3 million, everything-but-Rx on the contrary grew by 18.1% to 703.7 million. In the fourth quarter, DACH sales were EUR 228.7 million (previous year: 223.7 million). In the International segment (France, Belgium, Italy and the Netherlands), SHOP APOTHEKE EUROPE expanded sales by 39.6% to EUR 213.1 million in 2021 (EUR 152.7 million in the previous year) and by 44.1% to EUR 59.1 million in the fourth quarter.

CFO Jasper Eenhorst comments: "We achieved our full-year guidance of increasing total sales by around 10% thanks to an impressive 21% growth spurt from Q3 to Q4. Our propositions and marketing activities have successfully increased our total base of active customers by 0.5 million to 7.9 million. Our new logistics centre processed the orders flawlessly. We are ready for 2022."

All published figures are preliminary and unaudited. SHOP APOTHEKE EUROPE will publish the full annual report for the financial year 2021 on 2 March 2022.
 

About SHOP APOTHEKE EUROPE.

SHOP APOTHEKE EUROPE is one of Europe's leading and fastest-growing online pharmacies, currently operating in Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland.

Headquartered in the Dutch logistics hub of Sevenum near Venlo with locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Lille and Eindhoven, SHOP APOTHEKE EUROPE offers its customers a broad range of more than 100,000 original products at attractive prices: OTC, beauty and personal care products as well as prescription drugs, supplemented by high quality natural food and health products, low carb products and sports nutrition. Currently, 7.9 million active customers trust SHOP APOTHEKE EUROPE.

Since safe and reliable pharmaceutical advice are top priorities at SHOP APOTHEKE EUROPE, the e-pharmacy provides comprehensive pharmaceutical consulting services.

In preparation for the introduction of electronic prescriptions in Germany, the company will further improve the customer experience with a focus on disease-specific digital medication management services following the acquisition of SMARTPATIENT in January 2021. This is a key part of SHOP APOTHEKE EUROPE's strategy to transform itself from a pure online retailer into a truly customer-centric e-pharmacy platform.

SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 2016 and is part of the SDAX stock index.

PRESS CONTACTS.

Trade and popular media:
Sven Schirmer
Tel: +49 221 99 53 44 31
Email: [email protected]

Financial media:
Bettina Fries
Tel: +49 211 75 80 779
Email: [email protected]

Investor relations:
Carmen Herkenrath
Tel.: +31 77 850 6109
Email: [email protected]

Thomas Schnorrenberg
Mobile: +49 151 465 31317
Email: [email protected]



11.01.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: SHOP APOTHEKE EUROPE N.V.
Dirk Hartogweg 14
5928 LV Venlo
Netherlands
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail: [email protected]
Internet: www.shop-apotheke-europe.com
ISIN: NL0012044747, DE000A19Y072
WKN: A2AR94, A19Y07
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1266960

 
End of News DGAP News Service

1266960  11.01.2022 

fncls.ssp?fn=show_t_gif&application_id=1266960&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 177,39 283,99 539,71 701,01 968,06 1.060,32 1.270,00
EBITDA1,2 -8,84 -12,14 -15,56 -18,58 15,20 -38,73 -25,00
EBITDA-Marge3 -4,98 -4,27 -2,88 -2,65 1,57 -3,65 -1,97
EBIT1,4 -11,64 -19,20 -28,73 -33,45 -0,87 -65,70 -52,00
EBIT-Marge5 -6,56 -6,76 -5,32 -4,77 -0,09 -6,20 -4,09
Jahresüberschuss1 -18,45 -21,36 -33,61 -36,27 -16,77 -74,19 -57,00
Netto-Marge6 -10,40 -7,52 -6,23 -5,17 -1,73 -7,00 -4,49
Cashflow1,7 -17,21 -23,24 -23,54 -30,37 17,80 11,64 19,00
Ergebnis je Aktie8 -2,03 -2,25 -2,79 -2,78 -1,17 -4,15 -3,00
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Mazars

INVESTOR-INFORMATIONEN
©boersengefluester.de
Shop Apotheke Europe
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2AR94 88,000 Halten 1.601,54
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
110,00 0,00 0,00 -43,56
KBV KCV KUV EV/EBITDA
3,86 137,65 1,51 -34,53
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,00 0,00 0,00 14.04.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
05.05.2022 03.08.2022 31.10.2022 02.03.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
2,70% -19,00% -22,26% -47,12%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu SHOP APOTHEKE EUROPE N.V.  ISIN: NL0012044747 können Sie bei DGAP abrufen


E-Commerce , A2AR94 , SAE , XETR:SAE